Citigroup Inc Syndax Pharmaceuticals Inc Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Citigroup Inc holds 324,929 shares of SNDX stock, worth $6.67 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

324,929

Previous 162,406 100.07%

Holding current value

$6.67 Million

Previous $3.51 Million 120.38%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$19.71 - $24.57 $3.2 Million - $3.99 Million	162,523 Added 100.07%	324,929 $7.73 Million
Q4 2023 Feb 09, 2024	BUY	$11.39 - $21.67 $480,361 - $913,910	42,174 Added 35.08%	162,406 $3.51 Million
Q3 2023 Nov 09, 2023	BUY	$14.52 - $21.77 $51,110 - $76,630	3,520 Added 3.02%	120,232 $1.75 Million
Q2 2023 Aug 10, 2023	SELL	$19.35 - $22.31 $8.59 Million - $9.9 Million	-443,703 Reduced 79.17%	116,712 $2.44 Million
Q1 2023 May 11, 2023	BUY	$20.66 - $28.98 $6.08 Million - $8.53 Million	294,482 Added 110.74%	560,415 $11.8 Million

Q4 2022 Feb 09, 2023	SELL	$20.64 - $26.24 $5.47 Million - $6.95 Million	-265,053 Reduced 49.92%	265,933 $6.77 Million
Q3 2022 Nov 10, 2022	BUY	$18.51 - $24.79 $1.24 Million - $1.66 Million	67,007 Added 14.44%	530,986 $12.8 Million
Q2 2022 Aug 10, 2022	BUY	$13.64 - $19.48 $6 Million - $8.57 Million	439,793 Added 1818.38%	463,979 $8.93 Million
Q1 2022 May 12, 2022	SELL	$14.84 - $22.15 $1.57 Million - $2.35 Million	-105,901 Reduced 81.41%	24,186 $421,000
Q4 2021 Feb 10, 2022	BUY	$15.23 - $22.47 $1.16 Million - $1.71 Million	76,023 Added 140.62%	130,087 $2.85 Million
Q3 2021 Nov 10, 2021	BUY	$13.87 - $19.8 $749,867 - $1.07 Million	54,064 New	54,064 $1.03 Million

Others Institutions Holding SNDX

# of Institutions

195

Shares Held

90M

Call Options Held

353K

Put Options Held

207K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $1.16B
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account